These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 11221866

  • 1. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK, Yong WH, Incardona F, Thompson RC, Riedinger MS, Zhang W, Prins RM, Black KL.
    Cancer Res; 2001 Feb 01; 61(3):842-7. PubMed ID: 11221866
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma.
    Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M.
    Anticancer Res; 2002 Feb 01; 22(2A):613-21. PubMed ID: 12014629
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of immunomodulation in human glioblastoma.
    Avril T, Vauleon E, Tanguy-Royer S, Mosser J, Quillien V.
    Immunotherapy; 2011 Apr 01; 3(4 Suppl):42-4. PubMed ID: 21524170
    [Abstract] [Full Text] [Related]

  • 6. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW.
    Clin Cancer Res; 2005 Jul 15; 11(14):5292-9. PubMed ID: 16033848
    [Abstract] [Full Text] [Related]

  • 7. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
    Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R.
    Clin Cancer Res; 2005 Aug 15; 11(16):5900-11. PubMed ID: 16115932
    [Abstract] [Full Text] [Related]

  • 8. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy.
    Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C.
    J Clin Neurosci; 2008 Feb 15; 15(2):114-21. PubMed ID: 18083572
    [Abstract] [Full Text] [Related]

  • 9. T cell adoptive immunotherapy of newly diagnosed gliomas.
    Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J, Cohen PA, Shu S.
    Clin Cancer Res; 2000 Jun 15; 6(6):2209-18. PubMed ID: 10873070
    [Abstract] [Full Text] [Related]

  • 10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Jun 15; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2.
    Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G.
    Br J Cancer; 2001 Nov 30; 85(11):1722-30. PubMed ID: 11742494
    [Abstract] [Full Text] [Related]

  • 13. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma.
    Hegmans JP, Veltman JD, Lambers ME, de Vries IJ, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG.
    Am J Respir Crit Care Med; 2010 Jun 15; 181(12):1383-90. PubMed ID: 20167848
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
    Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R.
    Br J Cancer; 2003 Oct 06; 89(7):1172-9. PubMed ID: 14520441
    [Abstract] [Full Text] [Related]

  • 19. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A, Oh S, Gharagozlou S, Vedi RN, Ericson K, Low WC, Chen W, Ohlfest JR.
    J Immunother; 2007 Oct 06; 30(8):789-97. PubMed ID: 18049330
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.